Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1]. Group 1: Allegations Against BioAge - The lawsuit claims that BioAge made false and misleading statements in its registration statement and prospectus regarding the STRIDES Phase 2 trial for azelaprag [3]. - Specific allegations include the failure to disclose the potential for liver transaminitis in previous clinical trials and preclinical studies [3]. - The complaint asserts that BioAge misrepresented safety concerns and the expected outcomes of the STRIDES clinical trial, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Legal Process for Investors - Investors in BioAge have until March 10, 2025, to seek appointment as lead plaintiff in the class action lawsuit [4]. - A lead plaintiff represents the interests of all class members and typically has the largest financial stake in the case [4]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to recover any potential damages [4].
BIOA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against BioAge Labs, Inc. (BIOA)